Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 7;5(1):36-45.
doi: 10.1002/osp4.309. eCollection 2019 Feb.

A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function

K G Kheniser  1 , S R Kashyap  1 , T Kasumov  2
Affiliations
Review

A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function

K G Kheniser et al. Obes Sci Pract. .

Abstract

Aims: Metformin is a commonly prescribed anti-hyperglycaemic pharmacological agent, and it remains a staple in the management of type II diabetes. In addition to metformin's glucose lowering effects, research has indicated that metformin inhibits glycation-mediated and oxidative modification of lipoprotein residues. The purpose was to discuss the effects of metformin as it relates to high-density lipoprotein (HDL) and low-density lipoprotein (LDL) modification.

Materials and methods: The purpose was to conduct a narrative and pragmatic review on the effects of metformin as it pertains to HDL and LDL modification.

Results: High-density lipoprotein (HDL) concentration is a quantitative measure and therefore does not provide insight into its function, which is a qualitative property. Dysfunctional HDLs are unable to carry out functions normally associated with HDL because they can be modified by glycating agents. Metformin may counteract HDL dysfunction by abating HDL modification. Reductions in HDL modification may improve reverse cholesterol transport ability and thus possibly diminish cardiovascular risk. Similarly, metformin-mediated attenuations in LDL modification may reduce their atherogenic potency.

Conclusion: Metformin may partially ameliorate HDL dysfunction and reduce LDL modification by inhibiting alpha-dicarbonyl-mediated modification of apolipoprotein residues; consequently, the results are salient because cardiovascular disease incidence may be reduced given that reverse cholesterol transport activity predicts risk, and modified LDL are proatherogenic.

Keywords: Gycation; Lipoproteins; Metformin; Type II diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of hyperglycaemia. HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.
Figure 2
Figure 2
High‐density lipoprotein glycation and metformin. Simplified view of the effects of glycation. Metformin inhibits glycation by reducing blood glucose levels and glycating species (carbonyl compounds) and oxidative stress. ApoA‐1, Apolipoprotein A1; HDL, high‐density lipoprotein.
Figure 3
Figure 3
High‐density lipoprotein dysfunction: clinical repercussions. HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci 2014; 11: 1185–1200. - PMC - PubMed
    1. Wallander M, Axelsson K, Nilsson A, Lundh D, Lorentzon M. Type 2 diabetes and risk of hip fractures and non‐skeletal fall injuries in the elderly: a study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res 2017; 32: 449–460. - PubMed
    1. Association AD . Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes‐2018. Daibetes Care 2018; 41: S73–S85. - PubMed
    1. Gallo A, Ceolotto G, Pinton P, et al. Metformin prevents glucose‐induced protein kinase C‐B2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 2005; 54: 1123–1131. - PubMed
    1. Ding H, Aljofan M, Triggle C. Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 2007; 212: 682–689. - PubMed

LinkOut - more resources